Tesamorelin, an analogue of growth hormone releasing hormone (GHRH), mirrors the structure of standard GHRH, enhanced by the addition of an extra trans-3-hexanoic acid group. Developed by Theratechnologies in Canada, Tesamorelin earned FDA approval in 2010 as the latest drug for managing HIV-associated lipodystrophy. Beyond its approved use, the peptide has undergone exploration regarding its potential to enhance peripheral nerve regeneration and as a potential intervention for mild cognitive impairment (MCI), which precedes dementia.
Tesamorelin 5mg (Without mannitol)
$80.00
Product Usage: This PRODUCT IS INTENDED AS A RESEARCH CHEMICAL ONLY. This designation allows the use of research chemicals strictly for in vitro testing and laboratory experimentation only. All product information available on this website is for educational purposes only. Bodily introduction of any kind into humans or animals is strictly forbidden by law. This product should only be handled by licensed, qualified professionals. This product is not a drug, food, or cosmetic and may not be misbranded, misused or mislabeled as a drug, food, or cosmetic.
Tesamorelin Structure
Sequence (Single Letter): Unk-Tyr-Ala-Asp-Ala-lle-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-lle-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu
Molecular Formula: C223H370N72O69S
Molecular Weight: 5195.908 g/mol
PubChem CID: 44147413
CAS Number: 901758-09-6
Guaranteed Checkout
-
Worldwide Shipping
-
Delivers in: 3-7 Working Days Shipping & Return